PRADAXA (DABIGATRAN ETEXILATE MESYLATE) — FDA Approval NDA214358 (BOEHRINGER INGELHEIM)
PRADAXA (DABIGATRAN ETEXILATE MESYLATE) — FDA Approval NDA214358 (BOEHRINGER INGELHEIM) is one of 9,000 drug approvals in the DrugApprovals dataset. Key details — Brand name: PRADAXA; Active ingredients: DABIGATRAN ETEXILATE MESYLATE; Application number: NDA214358.
| Brand name | PRADAXA |
|---|---|
| Active ingredients | DABIGATRAN ETEXILATE MESYLATE |
| Application number | NDA214358 |
| Sponsor | BOEHRINGER INGELHEIM |
| Dosage form | PELLETS |
| Route | ORAL |
| Marketing status | Prescription |
| Products in application | 6 |
| First approval date | 20210621 |
| Source | openFDA Drugs@FDA |
$1499/mo
Try DrugApprovals →